

2021年 業績

英文論文

1. Fujimoto N, Shiota M, Matsukawa T, Minato A, Tomisaki I, Ohnishi R, Eto M.
Three-month prostate-specific antigen level after androgen deprivation therapy predicts survival in patients with metastatic castration-sensitive prostate cancer.
In Vivo. 2021 Mar-Apr;35(2):1101-1108
2. Shiota M, Fujimoto N, Matsumoto T, Tsukahara S, Nagakawa S, Ueda S, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Eto M
Differential impact of TGFβ1 variation by metastatic status in androgen-deprivation therapy for prostate cancer.
Frontiers in Oncology. 2021 May 25;11:697955
3. Nagakawa S, Shiota M, Fujimoto N, Yamamoto Y, Blas L, Tsukahara S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Matsuyama H, Eto M.
The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer in a genome-wide association study.
Urologic Oncology. 2021 Oct;39(10):733.e17-733.e24
4. Tobu S, Udo K, Nishihara K, Miyajima S, Ando T, Onizuka C, Itesako T, Ashikari A, Hakariya T, Igawa T, Tanaka M, Shin T, Kamoto T, Nakagawa M, Saito S, Sakai H, Eto M, Kamba T, Fujimoto N, Noguchi M.
Surveillance of urachal abscess in the Kyushu–Okinawa area of Japan
International Journal of Urology. 2021 Oct;28(10):1008-1011
5. Shiota M, Fujimoto N, Sekino Y, Tsukahara S, Nagakawa S, Takamatsu D, Abe T, Kinoshita F, Ueda S, Ushijima M, Matsumoto T, Kashiwagi E, Inokuchi J, Uchiumi T, Oda Y, Eto M.
Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.
Andrologia. 2021 Nov 8:e14307.

6. Tomisaki I, Harada M, Tokutsu K, Minato A, Nagata Y, Kimuro R, Matsumoto M, Fujimoto N.
Impact of C-reactive protein flare response in patients with advanced urothelial carcinoma who received pembrolizumab.
In Vivo. 35(6):3563-3568. 2021.
7. Tomisaki I, Harada M, Minato A, Onishi R, Terado M, Inatomi H, Fujimoto N.
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
International Journal of Urology. 28(9):970-974. 2021.
8. Hamasuna R, Hanzawa H, Moritomo A, Matsumoto M, Aono H, Tomisaki I, Akasaka T, Fujimoto N, Jensen JS.
Analysis of fluoroquinolone-resistance using MIC determination and homology modelling of ParC of contemporary *Mycoplasma genitalium* strains.
Journal of Infection and Chemotherapy. 2021 23:S1341-1321X(21)00322-6. doi: 10.1016/j.jiac.2021.11.011. Online ahead of print. 2021.
9. Hamasuna R, Aono H, Kawaguchi K, Matsumoto M, Fujimoto N.
Sensitivity of a transcription-mediated amplification method (Aptima Mycoplasma genitalium assay) to detect M. genitalium in vitro
Journal of Infection and Chemotherapy, 27(4): 571-577, 2021
10. Hamasuna R, Yasuda M, Takahashi S, Uehara S, Kawai Y, Miyari I, Arakawa S, Kiyota H.
The Japanese association for infectious diseases/Japanese society of chemotherapy, The JAID/JSC guide/guideline to clinical management of infectious disease preparing committee, sexually transmitted infection working group
The Jaid/Jsc guideline to clinical management of infectious disease 1017 concerning male urethritis and related disorders
Journal of Infection and Chemotherapy, 27: 546-554, 2021
11. Wada K, Hamasuna R, Sadahira T, Araki M, Yamamoto S.
UAA-AAUS guideline for M. Genitalium and non-chlamydial non-gonococcal urethritis
Journal of Infection and Chemotherapy, 27: 1384-1388, 2021

12. Takahashi S, Arakawa S, Ishikawa K, Kamei J, Kobayashi K, Shigemura K, Takahashi S, Hiyama Y, Hamasuna R, Hayami H, Yazawa S, Yasuda M, Togo Y, Yamamoto S, Wada K, Watanabe T.
Guidelines for infection control in the urological field, including urinary tract management (revised second edition).
International Journal of Urology. 2021 Dec;28(12):1198-1211. doi: 10.1111/iju.14684. Epub 2021 Sep 3. PMID: 34480379
13. Wada K, Yokoyama T, Uno S, Araki M, Sadahira T, Maruyama Y, Acosta H, Nakajima H, Hiyama Y, Kunishima Y, Togo Y, Nukaya T, Yamada H, Shigemura K, Ito S, Tanimura M, Kobayashi K, Kitano H, Teishima J, Yasuda M, Uehara S, Hamasuna R, Watanabe T, Nakagawa T, Hayami H, Miyazaki J, Takahashi S, Masumori N, Ishikawa K, Kiyota H, Fujisawa M, Arakawa S, Nasu Y, Yamamoto S.
Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: Conducted by the Japanese Research Group for Urinary Tract Infections (JRGU).
Journal of Infection and Chemotherapy. 2021 Aug;27(8):1169-1180. doi: 10.1016/j.jiac.2021.03.012. Epub 2021 May 27. PMID: 33863634
14. Minato A, Noguchi H, Onishi R, Tomisaki I, Nakayama T, Fujimoto N.
Reduced expression level of GPX2 in T1 bladder cancer and its role in early-phase invasion of bladder cancer.
In Vivo. 35(2):753-759. 2021. doi: 10.21873/invivo.12316.
15. Minato A, Noguchi H, Moriya R, Higashijima K, Yamasaki G, Kimuro R, Hasegawa Y, Tomisaki I, Fujimoto N.
Evaluation of the extent of variant histology in urothelial carcinoma as a predictive marker of clinical outcomes after radical cystectomy.
Cancer Diagn Prognosis. 1(4): 345-351, 2021. doi:10.21873/cdp/10046
16. Minato A, Noguchi H, Kimuro R, Harada M, Nagata Y, Hasegawa Y, Tomisaki I, Harada K, Fujimoto N.
Prognostic value of squamous differentiation in upper tract urothelial carcinoma treated with radical nephroureterectomy.
Anticancer Research. doi: 10.21873/anticancers.11xxx. (in press)

17. Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Tamura S, Kuroiwa K, Seki N, Fujimoto N, Nakamura M.
The association of clinical outcomes with posttreatment changes in the relative eosinophil counts and neutrophil-to-eosinophil ratio in patients with advanced urothelial carcinoma treated with pembrolizumab.
Cancer Management and Research. 13: 8049-8056, 2021 Oct.
doi: 10.2147/CMAR.S333823.
18. Matsumoto M, Hamasuna R, Le T P, Fujimoto N, Matsumoto T.
Detection of *Neisseria gonorrhoeae* or *Chlamydia trachomatis* from oral wash specimens using the Abbott RealTime CT/NG assay and the Cobas 4800 CT/NG assay A prospective study.
Journal of Infection and Chemotherapy doi: 10.1016/j.jiac.2021.12.006. Online ahead of print, 2021.
19. Nagata Y, Matsukawa T, Tomisaki I, Fujimoto N.
Prognostic significance of 3-month prostate-specific antigen level following androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer.
Anticancer Research. Accepted.
20. Jiang G, Teramoto Y, Goto T, Mizushima T, Inoue S, Ide H, Nagata Y, Kashiwagi E, Baras AS, Netto GJ, Yang Z, Miyamoto H.
Identification of BXDC2 as a key downstream effector of the androgen receptor in modulating cisplatin sensitivity in bladder cancer.
Cancers (Basel). 2021 Feb 26;13(5):975.
21. Teramoto Y, Jiang G, Goto T, Mizushima T, Nagata Y, Netto GJ, Miyamoto H.
Androgen receptor signaling induces cisplatin resistance via down-regulating GULP1 expression in bladder cancer.
International Journal of Molecular Sciences. 2021 Sep 17;22(18):10030.
22. Harada M, Tomisaki I, Minato A, Onishi R, Terado M, Inatomi H, Fujimoto N.
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
International Journal of Urology. 28(9):970-974, 2021. doi: 10.1111/iju.14616

23. Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer. *S.Clin Cancer Res.* 2021 Nov 15;27(22):6164-6173. doi: 10.1158/1078-0432.CCR-21-2328. Epub 2021 Sep 15.
24. Shiota M, Akamatsu S, Narita S, Terada N, Fujimoto N, Eto M. Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer. *JMA J.* 2021 Apr 15;4(2):99-111. doi: 10.31662/jmaj.2021-0004. Epub 2021 Mar 26.
25. Shiota M, Akamatsu S, Narita S, Terada N, Fujimoto N, Eto M. Genetic polymorphisms and pharmacotherapy for prostate cancer. *Japan Medical Association Journal.* 2021 Apr 15;4(2):99-111.
26. Harada K, Shiota M, Minato A, Matsumoto M, Tomisaki I, Fujisawa M, Fujimoto N. Treatment strategies for metastatic castration-sensitive prostate cancer: From "All-comers" to "Personalized" approach. *OncoTargets and Therapy.* 2021 May 5;14:2967-2974
27. Fujimoto N, Harada K, Shiota M, Tomisaki I, Minato A, Nagata Y, Kimuro R, Harada M, Fujisawa M. Treatment of metastatic castration-resistant prostate cancer: Are PARP inhibitors shifting the paradigm? *Anticancer Research.* 2021 Oct;41(10):4687-4695
28. Matsumoto M, Yamamoto S. AAUS guideline for acute bacterial prostatitis 2021. *Journal of Infection and Chemotherapy* 27. 2021:1277-1283.

29.Hara K, Yamasaki K, Tahara M, Kimuro R, Yamaguchi Y, Suzuki Y, Kawabata H, Kawanami T, Fujimoto N, Yatera K.

Immune checkpoint inhibitors - induced eosinophilic pneumonia: A case report

Thoracic Cancer. 2021 Mar;12(5):720-724.